SOCS3-Luciferase mice: a model to identify mediators of leptin resistance
Elizabeth Lyn Cordonier,Tiemin Liu,Kenji Saito,Sylvia Siyu Chen,Yong Xu,Makoto Fukuda
DOI: https://doi.org/10.1096/fasebj.31.1_supplement.lb729
2017-01-01
Abstract:Obesity is characterized by diminished neural sensitivity to leptin, the most powerful anorectic hormone that critically maintains normal body weight, yet exact mechanisms underlying leptin resistance remain unclear. Suppressor of cytokine signaling (Socs3) has been identified as a critical mediator of neural leptin resistance. Since hypothalamic Socs3 is significantly increased under the conditions associated with leptin resistance such as overfeeding and in multiple obesity models, we assume that Socs3 induction could be used as a reliable readout to screen for compounds or pathways involved in leptin resistance. Thus, we have generated mice (SOCS3‐Luc) that express luciferase by introducing firefly luciferase‐polyA (Promega) into the ATG site of the Socs3 in a bacterial artificial chromosome (bMQ126k03) via homologous recombination. To validate SOCS3‐Luc mice, we injected lipopolysaccharide (LPS), a known, potent activator of Socs3, into the periphery of SOCS3‐Luc mice and their littermate controls (WT) and assessed luciferase activity and luciferase gene expression. SOCS3‐Luc mice treated with LPS showed a 2‐fold (p<0.05, n=3) and 3.7‐fold (p<0.01, n=3) increase in luciferase activity in the hypothalamus and liver, respectively compared to mice treated with a dPBS vehicle control. Hypothalamic and liver samples from WT mice showed no luciferase activity. Luciferase gene expression was increased by 8.3 fold (p<0.01, n=3) and 7‐fold (p<0.01, n=3) in LPS‐treated hypothalamus and liver respectively, compared to dPBS treated SOCS3‐Luc animals. Previously we have shown that an organotypic brain slice model is a powerful tool to measure effects on hypothalamic leptin signaling that allows us to dissect signaling mechanisms of leptin resistance in the hypothalamus. Using the ex vivo slice model of SOCS3‐Luc, we next tested if luciferase activity is indeed altered by the known modulators of leptin sensitivity. Slices treated with LPS show a 3‐fold (p<0.01, n=3) increase in luciferase activity compared to their PBS controls. Forskolin, a previously reported inducer of leptin resistance, showed a 2.4‐fold (p<0.0001) increase in luciferase activity compared to slices treated with a DMSO vehicle control while metformin, which has previously been reported to sensitize leptin signaling showed a 3.5‐fold (p<0.0001) decrease in luciferase activity. These results confirm that organotypic brain slices prepared from SOCS3‐Luc mice can serve as a suitable screening tool. Future studies involve in vivo imaging of SOCS3‐Luc mice under various conditions such as fasting/refeeding and high fat diet feeding. Support or Funding Information Supported by USDA‐CRIS 625051000055, NIH‐P30DK079638, NIH‐R01DK104901, and NIH‐T32HD071839